Under construction – not a live service
Sign in
Taking people in ChinaPhase 2

Tests HRS-5965 capsules for long-term safety in primary IgA nephropathy

Tests HRS-5965 capsules over time in adults with a kidney disease called IgA nephropathy.

Plain-language title generated from the registry record
Registry title: A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy

Key facts

Where
Beijing, ChinaSee the site
Phase
Phase 2

Where in China

  • Peking University First HospitalBeijing, ChinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Chengdu Suncadia Medicine Co., Ltd.
Trial code
NCT07582133
Record updated
22 July 2026
Original description
This study aims to evaluate the long-term safety of HRS-5965 capsules in patients with primary IgA nephropathy, and also to assess its efficacy in reducing 24-hour urinary protein and delaying the decline in eGFR in these patients.Read full original descriptionShow less

A Multicenter, Open-label Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 Capsules in Patients With Primary IgA Nephropathy

This study aims to evaluate the long-term safety of HRS-5965 capsules in patients with primary IgA nephropathy, and also to assess its efficacy in reducing 24-hour urinary protein and delaying the decline in eGFR in these patients.

Inclusion: Patients with primary IgA nephropathy who completed treatment in Study HRS-5965-305, or who prematurely discontinued study drug during the maintenance phase following initiation of rescue therapy; Understand the research procedures and methods, voluntarily participate in this trial and sign the informed consent form in person.

Exclusion: Hypersensitivity to the study drug or its components；; History of immunodeficiency disorders；; History of invasive encapsulated bacterial infection；; History of malignant neoplasm；; The estimated glomerular filtration rate (eGFR) is less than 20 mL/min/1.73m2；.

ClinicalTrials.gov NCT07582133